Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesMesoblast Ltd

Mesoblast Ltd

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
2.03 AUD -0.14 ( 6.45%)
Last update at 2026-11-06T06:17:00Z
VOLUME
2548051
Market Cap
2817.85M

Momentum Score

…

Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Ryoncil for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, Duchenne muscular dystrophy, and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease; and Revascor for the treatment of hypoplastic left heart syndrome. The company is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; MPC-150-IM for the treatment or prevention of chronic heart failure; Ryoncil for the treatment of pediatric SR-aGVHD; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM; Grünenthal GmbH to develop and commercialize MPC-06-ID for the treatment of chronic low back pain due to degenerative disc disease in patients; and JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
2.02
Low
2.07
High
52 Week Price Range
1.74
Low
3.31
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Mesoblast develops allogeneic cellular medicines derived from mesenchymal lineage cells for inflammatory, cardiovascular and orthopedic conditions, advancing multiple clinical-stage candidates and manufacturing capabilities. Long-term growth drivers include potential regulatory approvals across indications, partnering and licensing revenue, and scalable cell-manufacturing that could support commercial roll-out. The company's appeal to investors derives from exposure to novel biologic therapies that may benefit from successful trials and commercialization.

Principal risks include significant regulatory and clinical trial uncertainty, potential need for additional financing to reach commercialization, and competitive pressures in cell therapy and biologics.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
2.17
Dividend Yield
-
Revenue TTM
120.25M
Revenue Per Share
0.09
Gross Profit TTM
96.22M
Debt / Equity
0.25
ROE
-9.86%
Net Debt
71.84M
ROCE
-7.41%
Diluted EPS TTM
-0.07

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Income before tax -56.89M -101.81M -88.15M -82.10M -91.59M
Net income -57.50M -102.14M -87.96M -81.89M -91.35M
Selling general administrative 57.35M 23.21M 23.63M 25.37M 27.21M
Selling and marketing expenses - 16.10M 15.72M 27.73M 30.76M
Gross profit 103.58M 12.07M -35.17M -47.42M -53.36M
Reconciled depreciation - 6.40M 4.67M 4.11M 4.38M
Ebit - -80.06M -57.97M -69.14M -80.95M
Ebitda - -73.66M -56.08M -65.03M -76.57M
Depreciation and amortization - 6.40M 1.90M 4.11M 4.38M
Operating income -51.25M -62.44M -84.15M -69.29M -80.57M
Other operating expenses - 79.64M 90.05M 76.79M 90.78M
Interest expense 19.87M 21.75M 20.66M 19.44M 16.91M
Tax provision 0.61M 0.33M -0.19M -0.21M -0.24M
Interest income 3.91M 3.55M 1.82M 18.78M 0.00M
Net interest income -17.96M -19.00M -18.83M -19.29M -17.29M
Income tax expense - 0.33M -0.19M -0.21M -0.24M
Total revenue 120.25M 17.20M 5.90M 7.50M 10.21M
Total operating expenses 171.50M 74.51M 48.98M 76.79M 90.78M
Cost of revenue 16.67M 5.13M 41.07M 54.92M 63.57M
Total other income expense net 12.32M -39.37M -4.00M 6.48M 6.27M
Net income from continuing ops -57.50M -102.14M -87.96M -81.89M -91.35M
Net income applicable to common shares - -102.14M -87.96M -81.89M -91.35M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total assets 773.08M 784.68M 669.15M 669.41M 662.14M
Intangible assets 431.92M 437.37M 441.28M 442.73M 444.20M
Other current assets - - - 0.40M 5.40M
Total liab 204.67M 187.24M 188.80M 167.58M 165.10M
Total stockholder equity 568.40M 597.44M 480.36M 501.84M 497.04M
Other current liab 8.91M 16.73M 4.65M 5.43M 2.19M
Common stock - - 1310.81M 1249.12M 1165.31M
Capital stock 1530.77M 1508.85M 1310.81M 1249.12M 1165.31M
Retained earnings -1068.40M -1010.90M -908.76M -820.80M -738.92M
Other liab - - - 19.11M 15.02M
Good will 134.45M 134.45M 134.45M 134.45M 134.45M
Other assets - - - 2.33M 1.93M
Cash 47.39M 161.16M 62.56M 70.92M 60.03M
Cash and equivalents - - - -0.00M 0.01M
Total current liabilities 81.11M 102.63M 73.24M 41.98M 51.37M
Current deferred revenue - - 45.04M 6.40M 17.91M
Net debt 71.84M - 56.36M 45.58M 46.87M
Short term debt - - 16.49M 10.01M 8.20M
Short long term debt 10.60M 54.16M 13.86M 5.95M 5.02M
Short long term debt total - - 118.92M 116.50M 106.91M
Other stockholder equity - - - -428.32M -426.39M
Property plant equipment - - - 6.49M 9.96M
Total current assets 197.49M 204.35M 86.46M 81.66M 69.84M
Long term investments 0.00M 1.39M 1.01M 1.76M 1.76M
Net tangible assets - - - -75.34M -81.61M
Net receivables 57.08M 13.91M 20.95M 7.00M 4.40M
Long term debt 108.64M 67.74M 100.48M 102.81M 91.62M
Inventory 28.11M 22.25M - - -
Accounts payable 34.51M 19.08M 7.07M 20.14M 23.08M
Accumulated other comprehensive income - - 78.30M 73.52M 70.65M
Non currrent assets other 0.38M 0.47M 0.48M 0.48M 1.68M
Non current assets total 575.59M 580.33M 582.69M 587.76M 592.30M
Capital lease obligations 8.10M 6.26M 4.58M 7.73M 10.27M
Long term debt total - - - 106.48M 98.70M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Investments -0.12M 0.12M -0.10M -0.19M -0.23M
Change to liabilities - - - -0.40M 4.78M
Total cashflows from investing activities - 0.12M -0.10M -0.19M -0.23M
Net borrowings -5.94M -9.77M -13.52M -2.66M -6.33M
Total cash from financing activities -15.33M 147.34M 40.25M 74.50M -9.87M
Change to operating activities - - - 0.43M -0.05M
Net income -57.50M -102.14M -87.96M -81.89M -91.35M
Change in cash -60.18M 98.59M -8.36M 10.87M -76.43M
Begin period cash flow 161.55M 62.96M 71.32M 60.45M 136.88M
End period cash flow 102.91M 161.55M 62.96M 71.32M 60.45M
Total cash from operating activities - -49.95M -48.46M -63.27M -65.78M
Issuance of capital stock 2.60M 161.21M 65.41M 88.64M 0.21M
Depreciation - 6.40M 4.67M 4.11M 4.38M
Other cashflows from investing activities - 0.56M -0.06M 0.07M -0.07M
Dividends paid 0.00M 0.00M 0.00M 0.00M 0.00M
Change to inventory - 0.83M 0.00M - -
Change to account receivables - 6.29M -15.47M -0.12M 0.14M
Sale purchase of stock - 168.03M 65.41M 88.64M 8.29M
Other cashflows from financing activities - -4.10M -11.63M -11.48M 48.17M
Change to netincome - - - 16.98M 16.32M
Capital expenditures 0.90M 0.73M 0.33M 0.31M 0.23M
Change in working capital - -3.04M -2.63M -2.47M 4.87M
Stock based compensation - 22.09M 5.87M 3.65M 5.54M
Other non cash items - 26.41M 31.78M 13.54M 11.02M
Free cash flow -44.73M -50.68M -48.79M -63.58M -66.01M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
MSB
Mesoblast Ltd		 -0.14
6.45%		 2.03 - 454.55 23.43 3.36 18.28 -9.86
CSL
CSL Ltd		 -0.36
0.18%		 202.04 - 22.57 6.15 4.48 4.82 10.06
TLX
TELIX Pharmaceuticals Ltd		 -0.41
2.91%		 13.67 93.87 166.67 5.37 6.37 3.85 47.29
NEU
Neuren Pharmaceuticals Ltd		 -
-%		 23.24 154.93 36.36 42.38 7.52 31.95 160.40
PYC
PYC Therapeutics Ltd		 -0.05
2.59%		 1.88 - 12.00 73.11 2.63 25.02 -8.41

Profile*

Mesoblast Ltd

Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Ryoncil for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, Duchenne muscular dystrophy, and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease; and Revascor for the treatment of hypoplastic left heart syndrome. The company is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; MPC-150-IM for the treatment or prevention of chronic heart failure; Ryoncil for the treatment of pediatric SR-aGVHD; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM; Grünenthal GmbH to develop and commercialize MPC-06-ID for the treatment of chronic low back pain due to degenerative disc disease in patients; and JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.

55 Collins Street, Melbourne, VIC, Australia, 3000

61 3 9639 6036

https://www.mesoblast.com

108

Name Title Year Born
Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons) Founder, CEO, MD, Chairman of Scientific Advisory Board & Exec. Director 1957
Dr. Eric A. Rose M.D. Chief Medical Officer & Exec. Director 1951
Mr. Andrew Chaponnel B.Com. Interim Chief Fin. Officer NA
Ms. Dagmar Rosa-Bjorkeson M.B.A., M.S. Chief Operating Officer 1964
Mr. Peter T. Howard B.Sc., L.L.B., BSc, LLB (Hons) Gen. Counsel & Corp. Exec. 1968
Mr. Roger D. Brown BA Head of Spinal Orthopedic Disorders NA
Mr. Michael Schuster M.B.A., MS, BSc, MBA Head of Pharma Partnering 1977
Ms. Geraldine Storton B.Sc., M.B.A., Bsc, MMS, MBA Head of Regulatory Affairs & Quality Management NA
Mr. Justin Horst B.S. Head of Manufacturing NA
Ms. Niva Sivakumar B.Com., L.L.B. Joint Company Sec. NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…